Vascular cognitive impairment (VCI) represents a broad spectrum of cognitive disorders resulting from cerebrovascular disease, encompassing both vascular dementia (VaD) and milder forms of cognitive impairment with a vascular etiology [1](https://pubmed.ncbi.nlm.nih.gov/21388955/). VCI is recognized as the second most common cause of dementia after Alzheimer's disease (AD), accounting for approximately 15-30% of all dementia cases worldwide, and represents a potentially preventable form of cognitive decline [2](https://pubmed.ncbi.nlm.nih.gov/21893684/). [@erkinjuntti2004]
The concept of VCI extends beyond traditional vascular dementia to include the entire range of cognitive deficits attributable to vascular causes, from mild cognitive impairment to full dementia. This broader classification reflects the understanding that cerebrovascular disease can produce diverse cognitive syndromes depending on lesion location, size, and burden [3](https://pubmed.ncbi.nlm.nih.gov/22850565/). Importantly, VCI often coexists with AD pathology (mixed dementia), and vascular changes may accelerate or exacerbate Alzheimer-type neurodegeneration. [@moorhouse2008]
Vascular cognitive impairment (VCI) represents a broad spectrum of cognitive disorders resulting from cerebrovascular disease, encompassing both vascular dementia (VaD) and milder forms of cognitive impairment with a vascular etiology [1](https://pubmed.ncbi.nlm.nih.gov/21388955/). VCI is recognized as the second most common cause of dementia after Alzheimer's disease (AD), accounting for approximately 15-30% of all dementia cases worldwide, and represents a potentially preventable form of cognitive decline [2](https://pubmed.ncbi.nlm.nih.gov/21893684/). [@erkinjuntti2004]
The concept of VCI extends beyond traditional vascular dementia to include the entire range of cognitive deficits attributable to vascular causes, from mild cognitive impairment to full dementia. This broader classification reflects the understanding that cerebrovascular disease can produce diverse cognitive syndromes depending on lesion location, size, and burden [3](https://pubmed.ncbi.nlm.nih.gov/22850565/). Importantly, VCI often coexists with AD pathology (mixed dementia), and vascular changes may accelerate or exacerbate Alzheimer-type neurodegeneration. [@moorhouse2008]
The pathophysiology of VCI involves disruption of neural circuits essential for memory, executive function, and behavioral control, primarily through ischemic injury to strategically important brain regions. Unlike AD, which is characterized by progressive neuronal loss due to protein aggregation, VCI results from vascular insults that compromise cerebral blood flow and energy supply, leading to neuronal dysfunction and death [4](https://pubmed.ncbi.nlm.nih.gov/25315738/). [@wiesmann2013]
Vascular cognitive impairment represents a significant public health burden, particularly given its potentially preventable nature: [@blom2016]
| Parameter | Value | Notes | [@scheltens2018]
|-----------|-------|-------| [@sachdev2014]
| Prevalence of VCI | 5-15% of population >65 years | Increases with age | [@van2018]
| Proportion of all dementias | 15-30% | Second most common cause | [@georgakis2019]
| Annual incidence | 1-3% in population >65 years | Higher than AD in some regions | [@pantoni2010]
| Gender distribution | Slight male predominance | Related to higher vascular risk in men | [@iadecola2016]
| Geographic variation | Higher in regions with higher stroke prevalence | e.g., East Asia, Eastern Europe | [@staessen2016]
The development of VCI is strongly associated with cerebrovascular risk factors: [@duron2012]
Modifiable Risk Factors: [@ruitenberg2004]
Recent research has identified several promising blood-based biomarkers for VCI:
| Biomarker | Source | Potential Use |
|-----------|--------|---------------|
| Neurofilament light chain (NfL) | Blood | Marker of axonal damage |
| Tau proteins | Blood/CSF | Neuronal injury |
| Amyloid-beta 40/42 | Blood/CSF | AD co-pathology |
| Inflammatory markers | Blood | Disease activity |
Elevated neurofilament light chain levels correlate with white matter lesion burden and may predict progression from V-MCI to VaD. [@georgakis2019]
Advanced MRI techniques provide additional prognostic information:
VCI encompasses several distinct clinical syndromes, each associated with different vascular pathologies: [@bennett2007]
The most severe form of VCI, characterized by:
Resulting from small vessel disease affecting subcortical structures:
Characterized by multiple cortical infarcts:
Single or few strategically located infarcts causing dementia:
Coexistence of AD pathology and cerebrovascular disease:
Milder cognitive deficits with vascular etiology:
VCI results from various vascular pathologies affecting the brain:
| Pathology | Description | Key Features |
|-----------|-------------|--------------|
| Lipohyalinosis | Hyaline degeneration of vessel walls [9](https://pubmed.ncbi.nlm.nih.gov/25312042/) | Affects small penetrating arteries |
| Fibrinoid necrosis | Vessel wall deposition of fibrin [10](https://pubmed.ncbi.nlm.nih.gov/25551289/) | Associated with hypertension |
| Amyloid angiopathy | Amyloid deposition in vessel walls [11](https://pubmed.ncbi.nlm.nih.gov/25898847/) | Lobar hemorrhages, cortical microinfarcts |
| CADASIL | Notch3 mutations affecting small vessels [12](https://pubmed.ncbi.nlm.nih.gov/26369395/) | Hereditary small vessel disease |
The brain maintains constant blood flow through autoregulation:
Strategic brain regions are essential for cognitive function:
| Region | Function | Effect of Vascular Injury |
|--------|----------|--------------------------|
| Prefrontal cortex | Executive function, working memory | Impaired planning, judgment |
| White matter tracts | Information relay | Disconnection syndromes |
| Basal ganglia | Motor programming, cognition | Executive dysfunction |
| Thalamus | Sensory relay, cognition | Memory, attention deficits |
| Hippocampus | Memory consolidation | Memory impairment |
Cerebrovascular Risk Factors
↓
Small/Large Vessel Disease
↓
Chronic/Acute Hypoperfusion
↓
White Matter Ischemia + Infarcts
↓
Neural Circuitry Disruption
↓
Executive Dysfunction + Memory Loss
↓
Vascular Cognitive Impairment
VCI and AD frequently coexist through multiple mechanisms:
The cognitive profile in VCI differs from typical AD:
| Domain | VCI Pattern | AD Pattern |
|--------|------------|------------|
| Memory | Retrieval deficits, less severe | Encoding/Storage deficits, severe |
| Executive function | Early, prominent impairment | Late, less prominent |
| Language | Preserved initially | Early anomia |
| Visuospatial | Variable | Early impairment |
| Processing speed | Early, prominent slowing | Relatively preserved |
Focal Neurological Deficits:
| Phase | Characteristics |
|-------|-----------------|
| Preclinical | Vascular risk factors, subtle cognitive changes |
| MCI | Objective cognitive deficits, preserved function |
| Mild VaD | Mild dementia, some dependency |
| Moderate VaD | Moderate dementia, significant dependency |
| Severe VaD | Severe dementia, complete dependency |
| Test | Domain Assessed | Clinical Utility |
|------|-----------------|------------------|
| MMSE | Global cognition | Screening, staging |
| MoCA | Executive, attention | Sensitive to VCI |
| EXIT25 | Executive function | Frontal dysfunction |
| Trail Making A/B | Processing speed, switching | Executive assessment |
| Wisconsin Card Sort | Cognitive flexibility | Frontal lobe |
| Digit Span | Working memory | Attention |
| Clock Drawing | Visuospatial, executive | Screening |
Dementia:
Cerebrovascular disease:
Relationship:
| Modality | Findings in VCI |
|----------|-----------------|
| MRI (preferred) | White matter hyperintensities, lacunes, cortical infarcts, microbleeds |
| CT | White matter low attenuation, infarcts, atrophy |
| DWI | Acute infarcts |
| FLAIR | Chronic white matter disease |
| SWI | Microbleeds, cavernous malformations |
| Scale | Description |
|-------|-------------|
| Fazekas scale | White matter hyperintensity severity (0-6) |
| Wahlund scale | Regional white matter scoring |
| Medial temporal lobe atrophy | Differentiates AD from VCI |
| Stratification of small vessel disease | Combined MRI markers |
| Test | Purpose |
|------|---------|
| Blood glucose/HbA1c | Diabetes screening |
| Lipid panel | Hyperlipidemia |
| Homocysteine | Vascular risk marker |
| Inflammatory markers | Vasculitis workup |
| Carotid ultrasound | Stenosis assessment |
| Cardiac evaluation | Source of emboli |
| Condition | Key Distinguishing Features |
|-----------|----------------------------|
| Alzheimer's disease | Memory prominent, gradual onset, hippocampal atrophy |
| Lewy body dementia | Fluctuations, visual hallucinations, parkinsonism |
| Frontotemporal dementia | Behavioral changes, focal atrophy |
| Normal pressure hydrocephalus | Gait, urinary incontinence, dementia triad |
| Depression | Pseudodementia, mood symptoms |
| Metabolic dementia | Thyroid, B12 deficiency |
The cornerstone of VCI management is aggressive treatment of vascular risk factors:
| Medication Class | Evidence | Target BP |
|------------------|----------|-----------|
| ACE inhibitors | Strong evidence for stroke prevention | <130/80 mmHg |
| ARBs | Similar to ACEi | <130/80 mmHg |
| Calcium channel blockers | Effective in stroke prevention | <130/80 mmHg |
| Diuretics | Effective in stroke prevention | <130/80 mmHg |
Important: Mid-life hypertension is particularly important; control may reduce later dementia risk even if initiated later [6](https://pubmed.ncbi.nlm.nih.gov/22052877/).
| Risk Factor | Management | Target |
|-------------|------------|--------|
| Diabetes | Metformin, lifestyle | HbA1c <7% |
| Hyperlipidemia | Statins | LDL <70 mg/dL |
| Smoking | Cessation support | Complete cessation |
| Atrial fibrillation | Anticoagulation | INR 2-3 |
| Obesity | Diet, exercise | BMI <25 |
| Medication | Class | Efficacy | Notes |
|------------|-------|----------|-------|
| Donepezil | AChEI | Modest benefit | May improve cognition in VaD |
| Rivastigmine | AChEI | Modest benefit | Some studies positive |
| Galantamine | AChEI | Modest benefit | May help mixed dementia |
| Memantine | NMDA antagonist | Limited | Some benefit in VaD trials |
| Nimodipine | Calcium channel | Mixed | Not FDA approved for VCI |
| Symptom | Treatment |
|---------|-----------|
| Depression | SSRIs (citalopram, sertraline) |
| Apathy | Methylphenidate, dopaminergic agents |
| Psychosis | Risperidone, quetiapine (caution with stroke risk) |
| Agitation | Non-pharmacologic approaches first |
| Sleep disturbances | Sleep hygiene, melatonin |
| Strategy | Application |
|----------|-------------|
| Antiplatelet therapy | Aspirin, clopidogrel for secondary prevention |
| Anticoagulation | Warfarin, DOAC for AF |
| Carotid endarterectomy | Severe symptomatic stenosis |
| Statins | High-intensity for atherosclerosis |
VCI typically shows a more variable course than AD:
| Feature | VCI Pattern | AD Pattern |
|---------|-------------|------------|
| Progression | Variable, stepwise | Gradual, linear |
| Survival | Shorter average | Longer average |
| Response to treatment | May improve with vascular Rx | Slowly progressive |
| Plateaus | Common | Less common |
Positive prognostic factors:
Recent advances in neuroimaging and biomarker research are improving VCI diagnosis and prognostication. Blood-based biomarkers including neurofilament light chain (NfL) show promise for detecting neuronal injury in VCI, with elevated levels correlating with white matter lesion burden and cognitive decline[25]. PET imaging for amyloid and tau helps distinguish VCI from AD, while diffusion tensor imaging (DTI) provides sensitive measures of white matter integrity disruption[26]. Research on glymphatic system dysfunction as a contributor to VCI is emerging, as impaired glymphatic clearance may compound small vessel disease effects[27]. Clinical trials targeting vascular pathophysiology continue to explore the efficacy of various anti-inflammatory and neuroprotective agents in combination with vascular risk factor management.
Primary prevention focuses on reducing vascular risk factors before cognitive impairment develops:
Vascular Risk Factor Management:
Lifestyle Interventions:
For patients with established cerebrovascular disease:
| Intervention | Target Population | Benefit |
|--------------|-------------------|---------|
| Antiplatelet therapy | Post-stroke, non-AF | Recurrent stroke prevention |
| Anticoagulation | Atrial fibrillation | Stroke prevention |
| Carotid revascularization | Severe stenosis | Stroke prevention |
| Statin therapy | All VCI patients | Cardiovascular risk reduction |
The SPRINT-MIND trial demonstrated that intensive BP control (<120 mmHg) significantly reduced the incidence of MCI and dementia, supporting aggressive hypertension management as a cornerstone of VCI prevention.
Stroke frequently precipitates or exacerbates cognitive decline:
This entity represents the earliest stage of VCI:
The most common form of dementia in autopsy studies:
CADASIL represents the most extensively characterized monogenic cause of VCI, resulting from mutations in the [NOTCH3](/genes/notch3) gene on chromosome 19p13 [13](https://pubmed.ncbi.nlm.nih.gov/26369395/). This autosomal dominant condition manifests with recurrent subcortical ischemic strokes, progressive cognitive decline, and migraine with aura.
Pathophysiology: NOTCH3 mutations cause abnormal accumulation of the Notch3 extracellular domain in small arterial walls, particularly in leptomeningeal and penetrating cerebral arteries. This accumulation leads to progressive degeneration of vascular smooth muscle cells, vessel wall thickening, and luminal narrowing. The resulting chronic hypoperfusion produces the characteristic white matter changes and lacunar infarcts seen on MRI [14](https://pubmed.ncbi.nlm.nih.gov/25998549/).
Clinical Features:
CARASIL is a rare autosomal recessive disorder caused by mutations in the HTRA1 gene, presenting with a more severe phenotype than CADASIL and featuring prominent spondylosis and hair loss as distinguishing features [16](https://pubmed.ncbi.nlm.nih.gov/20301369/).
HERNS results from mutations in the COL4A1 gene, affecting type IV collagen in basement membranes. This disorder presents with multi-system vasculopathy including retinal vasculopathy, renal disease, and stroke-related cognitive decline [17](https://pubmed.ncbi.nlm.nih.gov/16452925/).
Fabry disease, caused by GLA gene mutations leading to alpha-galactosidase A deficiency, produces a progressive vasculopathy with cerebrovascular complications. Stroke occurs in approximately 6-10% of patients, with cognitive impairment developing in a significant proportion. Enzyme replacement therapy may reduce cerebrovascular event risk when initiated early [18](https://pubmed.ncbi.nlm.nih.gov/29883447/).
Mutations in the [VPS35](/genes/vps35) gene, primarily associated with late-onset familial Parkinson's disease, have been linked to a specific form of VCI characterized by progressive gait disturbance, parkinsonism, and cognitive decline. The mechanism involves impaired retrograde transport through the retromer complex, leading to endosomal dysfunction in both neuronal and vascular cells [19](https://pubmed.ncbi.nlm.nih.gov/29953854/).
White matter hyperintensities (WMH), visible as bright areas on T2/FLAIR MRI sequences, represent the structural substrate of VCI in most patients. These lesions reflect a combination of demyelination, axonal loss, and gliosis resulting from chronic hypoperfusion.
Chronic Hypertension → Lipohyalinosis of Perforating Arteries
↓
Reduced Cerebral Blood Flow
↓
Blood-Brain Barrier Dysfunction
↓
Perivascular Edema + Myelin Damage
↓
White Matter Hyperintensities (WMH)
The periventricular white matter is particularly vulnerable due to the limited collateral circulation of long penetrating arteries. The distal territories of these arteries, known as the "watershed" zones, experience the greatest perfusion deficit during episodes of systemic hypotension or local vascular compromise [20](https://pubmed.ncbi.nlm.nih.gov/29343764/).
| WMH Grade (Fazekas) | Description | Cognitive Impact |
|--------------------|-------------|------------------|
| 0 | No lesions | Normal cognition |
| 1 | Punctate lesions | Often asymptomatic, increased risk |
| 2 | Beginning confluence | Executive dysfunction, gait impairment |
| 3 | Large confluent lesions | Dementia, severe functional decline |
The volume of WMH correlates more strongly with cognitive impairment than the number of lacunar infarcts, suggesting that the diffuse disconnection of frontal-subcortical circuits is more functionally significant than focal lesions alone [21](https://pubmed.ncbi.nlm.nih.gov/30928549/).
Longitudinal MRI studies demonstrate that WMH volume increases at a rate of approximately 0.5-1.0 mL per year in patients with established small vessel disease. Key predictors of progression include:
The functional impact of vascular lesions depends critically on location:
| Region | Lesion Effect | Clinical Manifestation |
|--------|-------------|----------------------|
| Anterior limb of internal capsule | Disconnection of frontal-cortical circuits | Executive dysfunction, apathy |
| Thalamus | Disruption of thalamo-cortical pathways | Memory impairment, attention deficits |
| Globus pallidus | Motor-circuit disruption | Gait disturbance, parkinsonism |
| Pons | Motor pathway disconnection | Gait, balance dysfunction |
| Corona radiata | Multi-circuit disconnection | Global cognitive decline |
Single strategic infarcts in the thalamus or angular gyrus can produce disproportionate cognitive impairment relative to lesion size, demonstrating the critical role of these relay structures in maintaining cortical function [22](https://pubmed.ncbi.nlm.nih.gov/25315738/).
Growing evidence indicates that VCI and AD share several key molecular mechanisms, explaining the high prevalence of mixed pathology:
Blood-Brain Barrier (BBB) Dysfunction: Both conditions feature progressive BBB breakdown, allowing peripheral proteins and inflammatory mediators to enter the brain parenchyma. In VCI, BBB dysfunction results primarily from chronic hypoperfusion and hypertension-induced endothelial damage. In AD, amyloid-beta itself disrupts BBB tight junctions. The convergence of these mechanisms accelerates neuronal injury [23](https://pubmed.ncbi.nlm.nih.gov/30599464/).
Neuroinflammation: Microglial activation is prominent in both VCI and AD. In VCI, chronic ischemia activates microglia through damage-associated molecular patterns (DAMPs). In AD, amyloid and tau aggregates serve as activating ligands. The resulting neuroinflammation amplifies neuronal death in both conditions.
Oxidative Stress: Chronic hypoperfusion in VCI reduces cerebral oxygen delivery, leading to mitochondrial dysfunction and increased reactive oxygen species production. Oxidative stress promotes lipid peroxidation, protein oxidation, and DNA damage in neurons. Similar oxidative mechanisms operate in AD, where amyloid-induced oxidative stress is well-documented.
Tau Pathology in VCI: Elevated phosphorylated tau (p-tau) levels are detected in the CSF and blood of VCI patients, particularly those with coexisting AD pathology. Ischemia promotes tau phosphorylation through activation of cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase-3 beta (GSK3-beta), creating a mechanistic link between vascular injury and tau pathology [24](https://pubmed.ncbi.nlm.nih.gov/30928549/).
The glymphatic system, a perivascular waste clearance pathway dependent on astrocytic aquaporin-4 (AQP4) water channels, is emerging as a critical link between vascular dysfunction and neurodegeneration. In VCI, impaired glymphatic clearance results from multiple mechanisms:
This dysfunction may explain why VCI patients with minimal AD pathology still show elevated amyloid on PET imaging in some studies — the glymphatic impairment itself prevents normal protein clearance [25](https://pubmed.ncbi.nlm.nih.gov/29942379/).
Active clinical investigation targeting VCI mechanisms includes several promising therapeutic approaches:
| Trial | Phase | Intervention | Target | Status |
|-------|-------|-------------|--------|--------|
| NCT04865129 | II | Cilostazol + Donepezil | Cognitive outcomes in VaD | Recruiting |
| NCT05347004 | II | L-arginine | Cerebral blood flow enhancement | Active |
| NCT05154786 | II | Mesenchymal stem cells | Neurovascular repair | Phase 1 |
| NCT04224354 | II | Fingolimod | Neuroinflammation, neuroprotection | Completed |
| NCT03803579 | III | Huperzine A | Cholinergic enhancement in VCI | Recruiting |
Key mechanisms being targeted include:
Related Hypotheses: